US Bancorp DE increased its holdings in Avantor, Inc. (NYSE:AVTR – Free Report) by 85.5% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 11,135 shares of the company’s stock after purchasing an additional 5,133 shares during the period. US Bancorp DE’s holdings in Avantor were worth $180,000 as of its most recent SEC filing.
A number of other institutional investors also recently made changes to their positions in AVTR. Wealthquest Corp purchased a new stake in Avantor during the 1st quarter valued at $34,000. GAMMA Investing LLC boosted its position in Avantor by 121.6% during the 1st quarter. GAMMA Investing LLC now owns 3,747 shares of the company’s stock valued at $61,000 after buying an additional 2,056 shares during the period. Fifth Third Bancorp boosted its position in Avantor by 52.0% during the 1st quarter. Fifth Third Bancorp now owns 3,972 shares of the company’s stock valued at $64,000 after buying an additional 1,359 shares during the period. Signaturefd LLC boosted its position in Avantor by 19.8% during the 1st quarter. Signaturefd LLC now owns 5,470 shares of the company’s stock valued at $89,000 after buying an additional 904 shares during the period. Finally, Archer Investment Corp purchased a new stake in Avantor during the 1st quarter valued at $112,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.
Insider Activity
In related news, CAO Steven W. Eck sold 3,476 shares of the stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $11.39, for a total value of $39,591.64. Following the transaction, the chief accounting officer owned 55,068 shares in the company, valued at approximately $627,224.52. This represents a 5.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gregory L. Summe acquired 30,000 shares of the company’s stock in a transaction dated Friday, May 23rd. The shares were purchased at an average cost of $12.50 per share, for a total transaction of $375,000.00. Following the purchase, the director directly owned 100,000 shares in the company, valued at approximately $1,250,000. This trade represents a 42.86% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.20% of the company’s stock.
Analysts Set New Price Targets
View Our Latest Report on AVTR
Avantor Trading Down 0.5%
Avantor stock opened at $12.91 on Friday. The firm’s 50 day moving average price is $13.19 and its 200-day moving average price is $14.79. Avantor, Inc. has a 1 year low of $10.82 and a 1 year high of $27.83. The stock has a market cap of $8.80 billion, a P/E ratio of 13.04, a PEG ratio of 1.46 and a beta of 0.96. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.98 and a quick ratio of 0.67.
Avantor (NYSE:AVTR – Get Free Report) last issued its earnings results on Friday, August 1st. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Avantor had a net margin of 10.31% and a return on equity of 11.39%. The company had revenue of $1.68 billion for the quarter, compared to analysts’ expectations of $1.67 billion. During the same period in the prior year, the firm posted $0.25 earnings per share. The firm’s revenue for the quarter was down 1.1% compared to the same quarter last year. On average, equities analysts predict that Avantor, Inc. will post 1.06 earnings per share for the current fiscal year.
Avantor Company Profile
Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
Read More
- Five stocks we like better than Avantor
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Restaurant Stocks That Will Outperform in Q3 and Q4
- Stock Splits, Do They Really Impact Investors?
- The Midstream Energy Play That Keeps Powering Higher
- How to buy stock: A step-by-step guide for beginners
- Ethereum Near All-Time High: 3 Stocks Stacking ETH in Treasuries
Want to see what other hedge funds are holding AVTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avantor, Inc. (NYSE:AVTR – Free Report).
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.